RECCE PHARMACEUTICALS LTD(RCE.AU)

0.66-0.01-2.24%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

Company Profile
Company Name
RECCE PHARMACEUTICALS LTD
Market
ASX
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.recce.com.au
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United States. Its lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

1D
5D
Day
Week
Month

Loading ...

High

0.67

Open

0.67

Volume%

0.80

Low

0.65

Close

0.67

T/O Rate

0.07%

Most Discussed

{"pagemeta":{"title":"RECCE PHARMACEUTICALS LTD(RCE.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RECCE PHARMACEUTICALS LTD(RCE.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RECCE PHARMACEUTICALS LTD,RCE.AU,RECCE PHARMACEUTICALS LTD股票,RECCE PHARMACEUTICALS LTD股票老虎,RECCE PHARMACEUTICALS LTD股票老虎国际,RECCE PHARMACEUTICALS LTD行情,RECCE PHARMACEUTICALS LTD股票行情,RECCE PHARMACEUTICALS LTD股价,RECCE PHARMACEUTICALS LTD股市,RECCE PHARMACEUTICALS LTD股票价格,RECCE PHARMACEUTICALS LTD股票交易,RECCE PHARMACEUTICALS LTD股票购买,RECCE PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RECCE PHARMACEUTICALS LTD(RCE.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RECCE PHARMACEUTICALS LTD(RCE.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}},"tab":"community","symbol":"RCE.AU","data":{"stockData":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.655,"timestamp":1767935520000,"preClose":0.67,"halted":0,"volume":118216,"delay":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":289183422,"eps":-0.090423,"marketStatus":"Market Closed","change":-0.015,"latestTime":"01-09 16:12:00 AEDT","open":0.67,"high":0.67,"low":0.65,"amount":78430,"amplitude":0.029851,"askPrice":0.665,"askSize":414,"bidPrice":0.65,"bidSize":86598,"shortable":3,"etf":0,"ttmEps":-0.090423,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1768172400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.67,"openAndCloseTimeList":[[1767913200000,1767934800000]],"volumeRatio":0.7976400600259852,"lotSize":1,"tradeCurrency":"AUD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.295844694011928","cardData":[{"tweetId":"295844694011928","author":{"authorId":"4169784042383112","idStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":245,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Recce Pharmaceuticals (ASX:RCE) achieves 5,000 weekly doses of RECCE 327 under GMP","digest":"Recce Pharmaceuticals achieved a production of 5,000 doses per week of RECCE 327 under Good Manufacturing Practices. The milestone supports ongoing clinical trials, including Phase 1 Phase 2, and upcoming Phase 3 trials, meeting regulatory standards such as those set by the US Food and Drug Administration. The production achievement underscores Recce's commitment to delivering R327 to patients and advancing towards investigational new drug submission. <a href=\"https://visit.grafa.com/tiger-brokers-grafa-03-1060?utm_source=ttmfinancial&amp;medium=social&amp;campaign=207876\">Claim Now</a>","plainDigest":"Recce Pharmaceuticals achieved a production of 5,000 doses per week of RECCE 327 under Good Manufacturing Practices. The milestone supports ongoing clinical trials, including Phase 1 Phase 2, and upcoming Phase 3 trials, meeting regulatory standards such as those set by the US Food and Drug Administration. The production achievement underscores Recce's commitment to delivering R327 to patients and advancing towards investigational new drug submission. Claim Now","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1713237631797,"gmtModify":1713237639962,"symbols":["RCE.AU"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://community-static.tradeup.com/news/58bf5e0ff3943a866b2e0642acae8f9f"}],"repostCount":0,"viewCount":241,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/295844694011928","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":399,"displayRows":4,"strategy":"timeline","foldSize":0,"authorId":"4169784042383112"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.291214547460352","cardData":[{"tweetId":"291214547460352","author":{"authorId":"4169784042383112","idStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":245,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Recce Pharmaceuticals (ASX:RCE) granted key patent in Israel for anti-infectives RECCE 327 and RECCE 529","digest":"Recce Pharmaceuticals achieved a milestone as the State of Israel Patent Office granted a new Patent Family 4 for its anti-infectives, RECCE 327 and RECCE 529, extending until 2041. The patent covers the preparation process and usage of these anti-infectives for treating various bacterial and viral infections. It marks Recce's first patent in Israel, a country with a thriving pharmaceutical market valued at US$5.3 billion ($8.14 billion) in 2021. The development highlights the potential of Recce's products in combating antibiotic-resistant pathogens and emerging viral diseases globally. <a href=\"https://grafa.com/news/recce-pharmaceuticals--asx-rce--granted-key-patent-in-israel-for-anti-infectives-recce-327-and-recce-529-202865?referralcode=A314DFDBE96C354756A893C6E3E02493\">Read More</a> #","plainDigest":"Recce Pharmaceuticals achieved a milestone as the State of Israel Patent Office granted a new Patent Family 4 for its anti-infectives, RECCE 327 and RECCE 529, extending until 2041. The patent covers the preparation process and usage of these anti-infectives for treating various bacterial and viral infections. It marks Recce's first patent in Israel, a country with a thriving pharmaceutical market valued at US$5.3 billion ($8.14 billion) in 2021. The development highlights the potential of Recce's products in combating antibiotic-resistant pathogens and emerging viral diseases globally. Read More #","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1712123311688,"gmtModify":1712123319212,"symbols":["RCE.AU"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":111,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/291214547460352","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":548,"displayRows":4,"strategy":"timeline","foldSize":0,"authorId":"4169784042383112"}],"position":0}],"size":2},"newsData":null,"noticeData":{"listData":[],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.recce.com.au","stockEarnings":[{"period":"1week","weight":-0.018},{"period":"1month","weight":0.1391},{"period":"3month","weight":0.6173},{"period":"6month","weight":1.0469},{"period":"1year","weight":0.4056},{"period":"ytd","weight":0.0077}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.054},{"period":"6month","weight":0.105},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United States. Its lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.076706},{"month":2,"riseRate":0.1,"avgChangeRate":-0.046151},{"month":3,"riseRate":0.6,"avgChangeRate":0.093758},{"month":4,"riseRate":0.4,"avgChangeRate":0.137823},{"month":5,"riseRate":0.5,"avgChangeRate":-0.023787},{"month":6,"riseRate":0.5,"avgChangeRate":0.109046},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027543},{"month":8,"riseRate":0.4,"avgChangeRate":0.04119},{"month":9,"riseRate":0.2,"avgChangeRate":-0.083267},{"month":10,"riseRate":0.5,"avgChangeRate":0.015341},{"month":11,"riseRate":0.5,"avgChangeRate":0.092476},{"month":12,"riseRate":0.4,"avgChangeRate":0.022776}],"exchange":"ASX","name":"RECCE PHARMACEUTICALS LTD","nameEN":"RECCE PHARMACEUTICALS LTD"},"aProfile":null}}}